A Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Conditions:   Gastric Adenocarcinoma;   Advanced Solid Tumors;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Biological: AK104;   Drug: Oxaliplatin;   Drug: Capecitabine
Sponsors:   Akeso;   Akeso Pharmaceuticals, Inc.
Recruiting

https://ift.tt/2Iz6Mwc